RAP-011 augments callus formation in closed fractures in rats

ABSTRACT ACE‐011 is a bone anabolic agent generated by fusing the extracellular domain of the Activin Type 2A receptor (ActRIIA) to an IgG‐Fc. The orthopedic utility of ACE‐011 was investigated using a murine analogue, RAP‐011. Initially, a rat closed fracture model was tested using bi‐weekly (biw)...

Full description

Saved in:
Bibliographic Details
Published in:Journal of orthopaedic research 2016-02, Vol.34 (2), p.320-330
Main Authors: Morse, Alyson, Cheng, Tegan L., Peacock, Lauren, Mikulec, Kathy, Little, David G., Schindeler, Aaron
Format: Article
Language:English
Subjects:
activin
Animals
Biomechanical Phenomena
bone
bone formation
Bony Callus - drug effects
Drug Evaluation, Preclinical
fracture
Fractures, Bone - drug therapy
Male
orthopedics
Rats, Wistar
Recombinant Fusion Proteins - pharmacology
Recombinant Fusion Proteins - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT ACE‐011 is a bone anabolic agent generated by fusing the extracellular domain of the Activin Type 2A receptor (ActRIIA) to an IgG‐Fc. The orthopedic utility of ACE‐011 was investigated using a murine analogue, RAP‐011. Initially, a rat closed fracture model was tested using bi‐weekly (biw) 10 mg/kg RAP‐011. RAP‐011 significantly increased callus length and callus bone volume (BV, +43% at 6w, p 
ISSN:0736-0266
1554-527X
DOI:10.1002/jor.22985